From the Guidelines
For a 66-year-old woman, Xarelto (rivaroxaban) has an elimination half-life of approximately 5-9 hours, with complete elimination generally occurring after 4-5 half-lives, which translates to around 24-48 hours 1. The half-life of rivaroxaban can vary depending on several factors, including age and kidney function. In elderly patients, the half-life of rivaroxaban can range from 5-9 hours 1.
Factors Affecting Elimination
- Age: Older adults tend to clear the medication more slowly than younger individuals 1.
- Kidney function: Rivaroxaban is partially eliminated through the kidneys, so reduced kidney function can impact clearance time 1.
Clinical Considerations
- For medical procedures requiring complete elimination of anticoagulant effects, Xarelto is typically stopped 24-48 hours before the procedure, depending on the bleeding risk and the patient's kidney function 1.
- It's essential to never stop taking Xarelto without medical guidance due to increased stroke risk, especially in patients taking it for atrial fibrillation.
Key Takeaways
- The elimination half-life of rivaroxaban in a 66-year-old female is approximately 5-9 hours 1.
- Complete elimination of rivaroxaban generally occurs after 4-5 half-lives, which is around 24-48 hours 1.
- Kidney function and age are crucial factors affecting the elimination of rivaroxaban 1.
From the FDA Drug Label
The terminal elimination half-life is 11 to 13 hours in the elderly subjects aged 60 to 76 years The elimination half-life of Rivaroxaban (Xarelto) in a 66-year-old female is 11 to 13 hours 2.
From the Research
Elimination Half-Life of Rivaroxaban
- The elimination half-life of Rivaroxaban is not directly stated in the provided studies for a 66-year-old female.
- However, the pharmacokinetics of Rivaroxaban are discussed in several studies, including 3, which mentions that Rivaroxaban has a high peroral bioavailability and moderate pharmacokinetic variability.
- Study 3 also states that the absorption of Rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration.
- Additionally, study 4 discusses the impacts of concomitant verapamil administration and renal impairment on Rivaroxaban pharmacokinetics, but does not provide specific information on the elimination half-life.
- Study 5 presents a case of a 68-year-old male patient who was receiving Rivaroxaban, but does not provide information on the elimination half-life in a 66-year-old female.
- Study 6 summarizes current knowledge supporting the use of Rivaroxaban in patients with severe renal impairment, but does not provide specific information on the elimination half-life.
- Study 7 is not relevant to the question as it discusses a case of a 66-year-old woman with disseminated intravascular coagulation, lactic acidosis, and hypoglycemia, but does not mention Rivaroxaban or its pharmacokinetics.